Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device With Alternative Post-Implant Monotherapy

NCT06521463 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT06521463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06521463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device With Alternative Post-Implant Monotherapy
Lead sponsor
Boston Scientific Corporation
Phase
Not applicable
Overall status
Active, not recruiting
Start date
October 1, 2024
Completion date
January 31, 2027
Enrollment
1,857 (actual)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation, bleeding, stroke